SCLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. The trend is firmly bearish (SMA_200 > SMA_20 > SMA_5 and MACD below zero), insiders are aggressively selling (+145.8% last month), and the latest quarter showed declining revenue and gross margin. With no Intellectia buy signals today and sentiment/positioning not showing a clear bullish turn, the higher-probability move is further chop/down rather than an immediate, clean upside breakout. For an impatient trader, this is an avoid/sell until price reclaims the pivot (~10.21) and momentum turns up.
Trend and momentum are bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), which typically signals a sustained downtrend. MACD histogram is negative (-0.151) but “negatively contracting,” suggesting downside momentum may be easing, yet it has not flipped bullish. RSI_6 is ~21.6, which is deeply oversold (despite the provided label saying neutral), so a short-term bounce is possible—but oversold alone is not a buy signal in a strong downtrend. Key levels: near-term support is S1 ~8.661 (current 8.69 is sitting right on it); a clean break risks S2 ~7.705. Upside resistance is the pivot ~10.208, then R1 ~11.755. Pattern-based projection implies modest near-term drift (next day +0.31%, next week +0.49%) but a stronger next-month rebound potential (+9.25%); however, the current tape still favors selling rallies until the pivot is reclaimed.
Announcement of a $20M strategic investment in Quantum Scan Holdings to support development of preventive diagnostic/prognostic medical technologies—can improve narrative and optionality if it leads to partnerships or product milestones.
raises the chance of a reflex bounce.
Latest quarter: 2025/Q3. Revenue fell to 10.56M (-26.85% YoY) and gross margin dropped to 58.82% (-12.16% YoY), pointing to weakening top-line and profitability quality. Net income improved YoY (still deeply negative at -257.234M) and EPS improved YoY (still negative at -22.17), but these are improvement-from-a-worse-base effects rather than evidence of profitability; the business remains loss-making with deteriorating revenue/margins in the quarter.
No analyst rating or price target change data was provided, so there is no visible Wall Street trend to confirm a bullish turn. Pros (typical bull case): potential upside from strategic/tech investments and biotech/medtech optionality. Cons (typical bear case): shrinking revenue, margin compression, ongoing large losses, and heavy insider selling—overall the con side dominates on the data given.
